Literature DB >> 32959931

Nervonic acid limits weight gain in a mouse model of diet-induced obesity.

Laura J W Keppley1, Susan J Walker1, Alexis N Gademsey1, Jason P Smith1, Susanna R Keller2, Mark Kester1, Todd E Fox1,3.   

Abstract

Lipid perturbations contribute to detrimental outcomes in obesity. We previously demonstrated that nervonic acid, a C24:1 ω-9 fatty acid, predominantly acylated to sphingolipids, including ceramides, are selectively reduced in a mouse model of obesity. It is currently unknown if deficiency of nervonic acid-sphingolipid metabolites contribute to complications of obesity. Mice were fed a standard diet, a high fat diet, or these diets supplemented isocalorically with nervonic acid. The primary objective was to determine if dietary nervonic acid content alters the metabolic phenotype in mice fed a high fat diet. Furthermore, we investigated if nervonic acid alters markers of impaired fatty acid oxidation in the liver. We observed that a nervonic acid-enriched isocaloric diet reduced weight gain and adiposity in mice fed a high fat diet. The nervonic acid enrichment led to increased C24:1-ceramides and improved several metabolic parameters including blood glucose levels, and insulin and glucose tolerance. Mechanistically, nervonic acid supplementation increased PPARα and PGC1α expression and improved the acylcarnitine profile in liver. These alterations indicate improved energy metabolism through increased β-oxidation of fatty acids. Taken together, increasing dietary nervonic acid improves metabolic parameters in mice fed a high fat diet. Strategies that prevent deficiency of, or restore, nervonic acid may represent an effective strategy to treat obesity and obesity-related complications.
© 2020 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  ceramide; fatty acid oxidation; obesity; omega-9; sphingolipids

Year:  2020        PMID: 32959931     DOI: 10.1096/fj.202000525R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  6 in total

Review 1.  Contribution of specific ceramides to obesity-associated metabolic diseases.

Authors:  Philipp Hammerschmidt; Jens C Brüning
Journal:  Cell Mol Life Sci       Date:  2022-07-05       Impact factor: 9.207

2.  Nervonic Acid Attenuates Accumulation of Very Long-Chain Fatty Acids and is a Potential Therapy for Adrenoleukodystrophy.

Authors:  Marcia R Terluk; Julianne Tieu; Siddhee A Sahasrabudhe; Ann Moser; Paul A Watkins; Gerald V Raymond; Reena V Kartha
Journal:  Neurotherapeutics       Date:  2022-04-04       Impact factor: 6.088

3.  Sphingolipids and metabolic disease: Will the real killer please stand up?

Authors:  Thorsten Hornemann
Journal:  Mol Ther       Date:  2022-03-12       Impact factor: 12.910

4.  Flammulina velutipes Mycorrhizae Attenuate High Fat Diet-Induced Lipid Disorder, Oxidative Stress and Inflammation in the Liver and Perirenal Adipose Tissue of Mice.

Authors:  Zhen Luo; Qingying Gao; Yuanfei Li; Yifei Bai; Jing Zhang; Weina Xu; Jianxiong Xu
Journal:  Nutrients       Date:  2022-09-16       Impact factor: 6.706

Review 5.  Sphingolipids in metabolic disease: The good, the bad, and the unknown.

Authors:  Christopher D Green; Michael Maceyka; L Ashley Cowart; Sarah Spiegel
Journal:  Cell Metab       Date:  2021-07-06       Impact factor: 31.373

6.  Metabolomics Analysis on Obesity-Related Obstructive Sleep Apnea After Weight Loss Management: A Preliminary Study.

Authors:  Weijun Huang; Anyuan Zhong; Huajun Xu; Chong Xu; Anzhao Wang; Fan Wang; Xinyi Li; Yupu Liu; Jianyin Zou; Huaming Zhu; Xiaojiao Zheng; Hongliang Yi; Jian Guan; Shankai Yin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-03       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.